Non–Small-Cell Lung Cancer

Non–Small-Cell Lung Cancer Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Featured

Aaron Lisberg, MD, On Treatment Approaches for Oncogene-Driven NSCLC

Dr Lisberg discusses when to use checkpoint inhibitor therapy for targetable mutations in NSCLC, a recap of his presentation at the 2020 Personalized Therapies in Thoracic Oncology meeting.

Combining Immuno-Oncology and Standard Chemo in the Treatment of NSCLC

Solange Peters, MD, PhD, provides a summation of the Keynote-189, CheckMate 9LA, and CheckMate 227 clinical trials, and what the findings of these studies mean for the treatment of patients with…

Recent Advancements in the Treatment of HER2+ NSCLC

Solange Peters, MD, PhD, discusses the DESTINY trial and recent advancements made in the exploration of treatment options for patients with HER2-positive NSCLC.

Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC

David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.

Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC

Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.

Remarkable Breakthroughs in the Treatment of Advanced NSCLC

Martin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.

The Role of Surgery in Locally Advanced NSCLC

Jessica Donington, MD, discusses the role of surgery in managing patients with locally advanced NSCLC.

Fadi Braiteh, MD, Discusses the Ins and Outs of Entrectinib Therapy for NSCLC

Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.

Second-Line Therapies in the Treatment of NSCLC

Edward B. Garon, MD, MS, discusses second-line therapies for the treatment of patients with NSCLC.